TriangleInavolisib (NCT07054190)
Inavolisib trial for Breast Cancer (NCT07054190). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with untreated stage II–III, ER-positive, HER2-negative breast cancer, a PIK3CA mutation and Ki-67 of at least 5%.
The idea: combine oral inavolisib, which blocks PI3K growth signals, with ribociclib and either letrozole or giredestrant. Some groups start with two drugs before adding the third. Treatment precedes planned surgery, unless the cancer is inoperable.
This phase 2 study plans 120 patients. Hoffmann-La Roche sponsors the trial, with six recruiting US sites. It checks safety and tumor response to these combinations.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.